Literature DB >> 28297660

Progesterone Prevents High-Grade Serous Ovarian Cancer by Inducing Necroptosis of p53-Defective Fallopian Tube Epithelial Cells.

Na-Yiyuan Wu1, Hsuan-Shun Huang2, Tung Hui Chao2, Hsien Ming Chou2, Chao Fang3, Chong-Zhen Qin4, Chueh-Yu Lin5, Tang-Yuan Chu6, Hong Hao Zhou7.   

Abstract

High-grade serous ovarian carcinoma (HGSOC) originates mainly from the fallopian tube (FT) epithelium and always carries early TP53 mutations. We previously reported that tumors initiate in the FT fimbria epithelium because of apoptotic failure and the expansion of cells with DNA double-strand breaks (DSB) caused by bathing of the FT epithelial cells in reactive oxygen species (ROSs) and hemoglobin-rich follicular fluid (FF) after ovulation. Because ovulation is frequent and HGSOC is rare, we hypothesized that luteal-phase progesterone (P4) could eliminate p53-defective FT cells. Here we show that P4, via P4 receptors (PRs), induces necroptosis in Trp53-/- mouse oviduct epithelium and in immortalized human p53-defective fimbrial epithelium through the TNF-α/RIPK1/RIPK3/MLKL pathway. Necroptosis occurs specifically at diestrus, recovers at the proestrus phase of the estrus cycle, and can be augmented with P4 supplementation. These results reveal the mechanism of the well-known ability of progesterone to prevent ovarian cancer.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  high-grade serous ovarian carcinoma; necroptosis; progesterone; progesterone receptor

Mesh:

Substances:

Year:  2017        PMID: 28297660     DOI: 10.1016/j.celrep.2017.02.049

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  31 in total

1.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

2.  The Flavonoid Apigenin Is a Progesterone Receptor Modulator with In Vivo Activity in the Uterus.

Authors:  Matthew Dean; Julia Austin; Ren Jinhong; Michael E Johnson; Daniel D Lantvit; Joanna E Burdette
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

3.  Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.

Authors:  Holly R Harris; Megan S Rice; Amy L Shafrir; Elizabeth M Poole; Mamta Gupta; Jonathan L Hecht; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-13       Impact factor: 4.254

Review 4.  Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.

Authors:  Vineet K Dhiman; Michael J Bolt; Kevin P White
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

5.  Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study.

Authors:  Gustavo C Rodriguez; James Kauderer; Jessica Hunn; Larry G Thaete; William G Watkin; Samantha Russell; Michael Yozwiak; Jack Basil; Jean Hurteau; Shashikant Lele; Susan C Modesitt; Oliver Zivanovic; Hao Helen Zhang; Peter H Bartels; David S Alberts
Journal:  Cancer Prev Res (Phila)       Date:  2019-04-23

Review 6.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

7.  Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models.

Authors:  Laura J Mauro; Megan I Seibel; Caroline H Diep; Angela Spartz; Carlos Perez Kerkvliet; Hari Singhal; Elizabeth M Swisher; Lauren E Schwartz; Ronny Drapkin; Siddharth Saini; Fatmata Sesay; Larisa Litovchick; Carol A Lange
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

Review 8.  Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.

Authors:  Isao Otsuka
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 9.  Models for measuring metabolic chemical changes in the metastasis of high grade serous ovarian cancer: fallopian tube, ovary, and omentum.

Authors:  Hannah Lusk; Joanna E Burdette; Laura M Sanchez
Journal:  Mol Omics       Date:  2021-12-06

10.  Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

Authors:  Minh Tung Phung; Alice W Lee; Anna H Wu; Andrew Berchuck; Kathleen R Cho; Daniel W Cramer; Jennifer Anne Doherty; Marc T Goodman; Gillian E Hanley; Holly R Harris; Karen McLean; Francesmary Modugno; Kirsten B Moysich; Bhramar Mukherjee; Joellen M Schildkraut; Kathryn L Terry; Linda J Titus; Susan J Jordan; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-22       Impact factor: 4.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.